vs
AMERICAN SHARED HOSPITAL SERVICES（AMS）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是AMERICAN SHARED HOSPITAL SERVICES的18.2倍（$140.6M vs $7.7M）。VERACYTE, INC.净利率更高（29.3% vs -8.2%，领先37.4%）。VERACYTE, INC.同比增速更快（18.5% vs -14.8%）。VERACYTE, INC.自由现金流更多（$48.8M vs $-2.7M）。过去两年AMERICAN SHARED HOSPITAL SERVICES的营收复合增速更高（21.7% vs 20.5%）
美国共享医院服务公司为医疗机构提供放射治疗、立体定向放射外科及诊断成像设备的整体外包解决方案，免除医院高昂的前期资本投入，主要业务覆盖北美，同时服务拉美及部分亚太地区的公立、私立医院客户。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
AMS vs VCYT — 直观对比
营收规模更大
VCYT
是对方的18.2倍
$7.7M
营收增速更快
VCYT
高出33.3%
-14.8%
净利率更高
VCYT
高出37.4%
-8.2%
自由现金流更多
VCYT
多$51.5M
$-2.7M
两年增速更快
AMS
近两年复合增速
20.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.7M | $140.6M |
| 净利润 | $-631.0K | $41.1M |
| 毛利率 | 11.7% | 72.5% |
| 营业利润率 | -18.1% | 26.4% |
| 净利率 | -8.2% | 29.3% |
| 营收同比 | -14.8% | 18.5% |
| 净利润同比 | 52.5% | 704.8% |
| 每股收益（稀释后） | $-0.09 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSVCYT
| Q4 25 | $7.7M | $140.6M | ||
| Q3 25 | $7.2M | $131.9M | ||
| Q2 25 | $7.1M | $130.2M | ||
| Q1 25 | $6.1M | $114.5M | ||
| Q4 24 | $9.1M | $118.6M | ||
| Q3 24 | $7.0M | $115.9M | ||
| Q2 24 | $7.1M | $114.4M | ||
| Q1 24 | $5.2M | $96.8M |
净利润AMSVCYT
| Q4 25 | $-631.0K | $41.1M | ||
| Q3 25 | $-17.0K | $19.1M | ||
| Q2 25 | $-280.0K | $-980.0K | ||
| Q1 25 | $-625.0K | $7.0M | ||
| Q4 24 | $-1.3M | $5.1M | ||
| Q3 24 | $-207.0K | $15.2M | ||
| Q2 24 | $3.6M | $5.7M | ||
| Q1 24 | $119.0K | $-1.9M |
毛利率AMSVCYT
| Q4 25 | 11.7% | 72.5% | ||
| Q3 25 | 22.1% | 69.2% | ||
| Q2 25 | 23.1% | 69.0% | ||
| Q1 25 | 15.4% | 69.5% | ||
| Q4 24 | 35.3% | 66.4% | ||
| Q3 24 | 19.6% | 68.2% | ||
| Q2 24 | 35.0% | 68.1% | ||
| Q1 24 | 41.1% | 64.5% |
营业利润率AMSVCYT
| Q4 25 | -18.1% | 26.4% | ||
| Q3 25 | -4.8% | 17.4% | ||
| Q2 25 | -7.7% | -4.0% | ||
| Q1 25 | -21.3% | 2.5% | ||
| Q4 24 | -20.2% | 3.5% | ||
| Q3 24 | -12.7% | 10.4% | ||
| Q2 24 | -0.0% | 4.0% | ||
| Q1 24 | -1.6% | -4.8% |
净利率AMSVCYT
| Q4 25 | -8.2% | 29.3% | ||
| Q3 25 | -0.2% | 14.5% | ||
| Q2 25 | -4.0% | -0.8% | ||
| Q1 25 | -10.2% | 6.2% | ||
| Q4 24 | -14.6% | 4.3% | ||
| Q3 24 | -3.0% | 13.1% | ||
| Q2 24 | 51.0% | 5.0% | ||
| Q1 24 | 2.3% | -1.9% |
每股收益（稀释后）AMSVCYT
| Q4 25 | $-0.09 | $0.50 | ||
| Q3 25 | $0.00 | $0.24 | ||
| Q2 25 | $-0.04 | $-0.01 | ||
| Q1 25 | $-0.10 | $0.09 | ||
| Q4 24 | $-0.21 | $0.07 | ||
| Q3 24 | $-0.03 | $0.19 | ||
| Q2 24 | $0.55 | $0.07 | ||
| Q1 24 | $0.02 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $362.6M |
| 总债务越低越好 | $17.4M | — |
| 股东权益账面价值 | $24.0M | $1.3B |
| 总资产 | $55.5M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资AMSVCYT
| Q4 25 | $3.5M | $362.6M | ||
| Q3 25 | $5.1M | $315.6M | ||
| Q2 25 | $11.1M | $219.5M | ||
| Q1 25 | $11.2M | $186.1M | ||
| Q4 24 | $11.0M | $239.1M | ||
| Q3 24 | $13.8M | $274.1M | ||
| Q2 24 | $14.2M | $235.9M | ||
| Q1 24 | $12.8M | $209.2M |
总债务AMSVCYT
| Q4 25 | $17.4M | — | ||
| Q3 25 | $18.2M | — | ||
| Q2 25 | $19.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | $20.4M | — | ||
| Q3 24 | $14.4M | — | ||
| Q2 24 | $15.1M | — | ||
| Q1 24 | $15.6M | — |
股东权益AMSVCYT
| Q4 25 | $24.0M | $1.3B | ||
| Q3 25 | $24.6M | $1.3B | ||
| Q2 25 | $24.5M | $1.2B | ||
| Q1 25 | $24.6M | $1.2B | ||
| Q4 24 | $25.2M | $1.2B | ||
| Q3 24 | $26.4M | $1.2B | ||
| Q2 24 | $26.5M | $1.1B | ||
| Q1 24 | $22.8M | $1.1B |
总资产AMSVCYT
| Q4 25 | $55.5M | $1.4B | ||
| Q3 25 | $59.6M | $1.4B | ||
| Q2 25 | $63.5M | $1.3B | ||
| Q1 25 | $63.3M | $1.3B | ||
| Q4 24 | $60.2M | $1.3B | ||
| Q3 24 | $63.3M | $1.3B | ||
| Q2 24 | $60.8M | $1.2B | ||
| Q1 24 | $50.1M | $1.2B |
负债/权益比AMSVCYT
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-704.0K | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $-2.7M | $48.8M |
| 自由现金流率自由现金流/营收 | -34.8% | 34.7% |
| 资本支出强度资本支出/营收 | 25.7% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $-8.5M | $126.6M |
8季度趋势，按日历期对齐
经营现金流AMSVCYT
| Q4 25 | $-704.0K | $52.6M | ||
| Q3 25 | $1.7M | $44.8M | ||
| Q2 25 | $-372.0K | $33.6M | ||
| Q1 25 | $2.5M | $5.4M | ||
| Q4 24 | $274.0K | $24.5M | ||
| Q3 24 | $472.0K | $30.0M | ||
| Q2 24 | $1.3M | $29.6M | ||
| Q1 24 | $-1.9M | $-9.0M |
自由现金流AMSVCYT
| Q4 25 | $-2.7M | $48.8M | ||
| Q3 25 | $-2.0M | $42.0M | ||
| Q2 25 | $-2.3M | $32.3M | ||
| Q1 25 | $-1.5M | $3.5M | ||
| Q4 24 | $-4.4M | $20.4M | ||
| Q3 24 | $-407.0K | $27.7M | ||
| Q2 24 | $70.0K | $26.8M | ||
| Q1 24 | $-3.0M | $-11.1M |
自由现金流率AMSVCYT
| Q4 25 | -34.8% | 34.7% | ||
| Q3 25 | -28.3% | 31.8% | ||
| Q2 25 | -32.1% | 24.8% | ||
| Q1 25 | -24.7% | 3.1% | ||
| Q4 24 | -48.4% | 17.2% | ||
| Q3 24 | -5.8% | 23.9% | ||
| Q2 24 | 1.0% | 23.4% | ||
| Q1 24 | -58.4% | -11.5% |
资本支出强度AMSVCYT
| Q4 25 | 25.7% | 2.7% | ||
| Q3 25 | 51.6% | 2.1% | ||
| Q2 25 | 26.9% | 1.0% | ||
| Q1 25 | 65.7% | 1.6% | ||
| Q4 24 | 51.4% | 3.5% | ||
| Q3 24 | 12.6% | 1.9% | ||
| Q2 24 | 17.2% | 2.4% | ||
| Q1 24 | 22.7% | 2.2% |
现金转化率AMSVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | 0.36× | 5.16× | ||
| Q1 24 | -15.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMS
| Direct Patient Services | $4.0M | 51% |
| Rental Income From Medical Services | $2.7M | 35% |
| Pbrt Services | $1.2M | 15% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
